Autres langues Aligos Therapeutics, Inc.

Actions

ALGS

US01626L1052

Marché Fermé - Nasdaq Autres places de cotation 22:30:00 03/05/2024			Varia. 5j.	Varia. 1 janv.
0,8101 ^USD	-4,24%		+3,59%	+22,00%

03/04	Aligos Therapeutics, Inc. annonce le dosage des premiers sujets de l'étude de phase 2a HERALD de l'ALG-055009 chez des sujets atteints de MASH	CI
27/03	Aligos Therapeutics présente à l'APASL 2024 des données cliniques positives issues des études de phase 1 ALG-055009 et ALG-000184	CI

Autres langues

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

Aligos Therapeutics to Announce 1st Quarter 2024 Financial Results on May 7, 2024	30/04
Aligos Therapeutics to Announce 1st Quarter 2024 Financial Results on May 7, 2024	30/04
Aligos Therapeutics Presents Positive Clinical Data at ESCMID 2024 from the ALG-097558 Phase 1 Study	25/04
Aligos Therapeutics Presents Positive Clinical Data at ESCMID 2024 from the ALG-097558 Phase 1 Study	25/04
Aligos Therapeutics Mourns the Passing of MASH Industry Leader Stephen A. Harrison, MD	25/04
Aligos Therapeutics Mourns the Passing of MASH Industry Leader Stephen A. Harrison, MD	25/04
Aligos Therapeutics to Participate in the Piper Sandler Spring Biopharma Symposium 2024	09/04
Aligos Therapeutics Announces First Subjects Dosed in the Phase 2a HERALD Study of ALG-055009 in MASH Subjects	03/04
Aligos Therapeutics Announces First Subjects Dosed in the Phase 2a HERALD Study of ALG-055009 in MASH Subjects	03/04
Aligos Therapeutics, Inc. Announces First Subjects Dosed in the Phase 2a HERALD Study of ALG-055009 in MASH Subjects	03/04
Aligos Therapeutics Presents Positive Clinical Data at APASL 2024 from ALG-055009 and ALG-000184 Phase 1 Studies	27/03
Aligos Therapeutics Presents Positive Clinical Data at APASL 2024 from ALG-055009 and ALG-000184 Phase 1 Studies	27/03
Aligos Therapeutics Announces the Initiation of the Phase 2a HERALD Study of ALG-055009 in MASH Subjects	18/03
Aligos Therapeutics Announces the Initiation of the Phase 2a HERALD Study of ALG-055009 in MASH Subjects	18/03
Aligos Therapeutics, Inc. Announces the Initiation of the Phase 2a HERald Study of ALG-055009 in MASH Subjects	18/03
Aligos Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	12/03
Aligos Therapeutics Reports Recent Business Progress and Fourth Quarter and Full Year 2023 Financial Results	12/03
Aligos Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	12/03
Aligos Therapeutics to Announce 4th Quarter 2023 Financial Results on March 12, 2024	05/03
Aligos Therapeutics To Participate in the Leerink Partners Global Biopharma Conference 2024	26/02

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Autres langues Aligos Therapeutics, Inc.

Actions

ALGS

US01626L1052

Autres langues

Filtres